http://www.avibio.com/ AVI BioPharma News and Press Releases Mon, 8 Sep 2008 06:30:00 PDT http://www.avibio.com/pr/pr389.php Transitioning an Antisense Pioneer into a Leading RNA-based Drug Discovery and Development Company [more...] Mon, 8 Sep 2008 06:30:00 PDT http://www.avibio.com/pr/pr389.php http://www.avibio.com/pr/pr388.php CORVALLIS, OR — September 8, 2008 — AVI BioPharma, Inc. (NASDAQ: AVII), announced today that it will host a breakfast meeting for analysts, brokers, investors and the Company’s shareholders on Wednesday, September 10, 2008, from 7:30 a.m. to 10:30 a.m. EDT at the Harvard Club of New York City. AVI’s senior management team will be joined by Dr. Francesco Muntoni, Professor of Pediatric Neurology, University College London Institute of Child Health and Ben Johnson, Engineering Manager at Global Therapeutics, a Cook Medical Company and partner with AVI in the development of the new GTX drug-eluting stent platform utilizing AVI-5126 for the reduction of cardiovascular restenosis. [more...] Mon, 8 Sep 2008 06:30:00 PDT http://www.avibio.com/pr/pr388.php http://www.avibio.com/pr/pr387.php CORVALLIS, OR — August 11, 2008 — AVI BioPharma, Inc. (NASDAQ: AVII) today reported financial results for the three and six months ending June 30, 2008. The Company also reported that it has received approval from the Medicine and Healthcare Product Regulatory Agency (MHRA) to conduct its systemic trial of AVI-4658 in the treatment of Duchenne Muscular Dystrophy in the United Kingdom and also updated the new additions to its senior management team. [more...] Mon, 11 Aug 2008 06:00:00 PDT http://www.avibio.com/pr/pr387.php